NasdaqGS:NKTX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	10	-164	-189	-122	5
12/31/2025	N/A	-140	-144	-112	6
12/31/2024	N/A	-118	-100	-111	6
3/31/2024	N/A	-116	-117	-94	N/A
12/31/2023	N/A	-118	-114	-86	N/A
9/30/2023	N/A	-122	-127	-70	N/A
6/30/2023	N/A	-125	-123	-65	N/A
3/31/2023	N/A	-119	-110	-59	N/A
12/31/2022	N/A	-114	-104	-57	N/A
9/30/2022	N/A	-104	-80	-67	N/A
6/30/2022	N/A	-98	-78	-71	N/A
3/31/2022	N/A	-93	-77	-72	N/A
12/31/2021	N/A	-86	-73	-68	N/A
9/30/2021	N/A	-81	-68	-63	N/A
6/30/2021	N/A	-72	-62	-57	N/A
3/31/2021	N/A	-102	-56	-50	N/A
12/31/2020	N/A	-91	-51	-44	N/A
9/30/2020	N/A	-84	-44	-37	N/A
6/30/2020	0	-73	-36	-30	N/A
3/31/2020	0	-27	-27	-23	N/A
12/31/2019	0	-21	-20	-18	N/A
12/31/2018	7	0	-6	-5	N/A

アナリストによる今後の成長予測

収入対貯蓄率: NKTX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: NKTX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: NKTX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: NKTX来年は収益がないと予測されています。

高い収益成長: NKTX来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: NKTXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Nkarta 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target increased by 7.7% to US$16.00

Price target decreased by 11% to US$17.38

Price target decreased to US$30.36

Price target decreased to US$43.56

Price target decreased to US$44.11

Price target decreased to US$64.71

Recent updates

Nkarta, Inc. Appoints George Vratsanos as Board of Directors

Nkarta: A Look Into Q1 Results And Upcoming Catalysts

Nkarta, Inc., Annual General Meeting, Jun 13, 2024

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Nkarta, Inc. has completed a Follow-on Equity Offering in the amount of $240.10001 million.

New minor risk - Shareholder dilution

Nkarta: NK Cell Therapy Advancement On Two Fronts

Nkarta, Inc. has filed a Follow-on Equity Offering in the amount of $240.10001 million.

CEO, President & Director notifies of intention to sell stock

Nkarta: Possible Upside From H1 Update, If Positive

CEO, President & Director recently sold US$85k worth of stock

Price target increased by 7.7% to US$16.00

Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Nkarta, Inc. Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Price target decreased by 11% to US$17.38

We're Keeping An Eye On Nkarta's (NASDAQ:NKTX) Cash Burn Rate

New minor risk - Market cap size

Nkarta, Inc. Appoints Alyssa Levin as Chief Financial Officer

Nkarta, Inc. Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

New minor risk - Share price stability

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Nkarta, Inc. to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Insufficient new directors

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Nkarta, Inc. Promotes David R. Shook to Chief Medical Officer

Price target decreased to US$30.36

Nkarta, Inc. Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

High number of new directors

Nkarta, Inc. to Report Q3, 2022 Results on Nov 09, 2022

CEO, President & Director notifies of intention to sell stock

Nkarta GAAP EPS of -$0.61

Chief Financial & Business Officer exercised options and sold US$71k worth of stock

Nkarta, Inc. Announces Executive Changes

Price target decreased to US$43.56

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Nkarta: A Promising Natural Killer Cell Play

Price target decreased to US$44.11

Nkarta, Inc. Announces Executive Changes

High number of new directors

Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs

Nkarta, Inc., Annual General Meeting, Jun 08, 2022

Nkarta, Inc. Appoints Angela M. Thedinga to its Board of Directors

Price target decreased to US$64.71

Nkarta, Inc. Presents NKX019 Trial in Progress Poster At the 2021 ASH Annual Meeting and Exposition

Insider notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Insider exercised options and sold US$118k worth of stock

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Chief Scientific Officer exercised options and sold US$62k worth of stock

Nkarta, Inc.(NasdaqGS:NKTX) dropped from Russell 2500 Growth Index

CEO, President & Director notifies of intention to sell stock

Insider notifies of intention to sell stock

Chief Financial & Business Officer notifies of intention to sell stock

Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer exercised options and sold US$62k worth of stock

Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies

Nkarta gets greenlight from the FDA for NKX019 cancer study

CEO, President & Director notifies of intention to sell stock

Chief Financial & Business Officer exercised options and sold US$246k worth of stock

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

New 90-day high: US$71.96

New 90-day high: US$35.74

New 90-day high: US$35.43

Nkarta Announces Treatment of First Patient in First-In-Human Clinical Trial of Engineered Nkg2d-Based Nk Cell Cancer Immunotherapy Nkx101

Nkarta Announces Presentation of Preclinical Data on NKX019

Nkarta, Inc. Announces Executive Changes

First half earnings released